This post was originally published on this site
The company announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis.
Shares closed more than 10% lower today.
BofA Securities initiated coverage on Autoliv, Inc. (ALV) with a Buy rating and a price target of $130.00.
“Compared to its high watermark of $7.9/sh (FY17), we see c50/61% EPS growth by FY25/26E, 70% driven by organic profit growth and 30% by a $1.5bn share buy-back program,” said the firm.
Citi initiated coverage on BioMarin Pharmaceutical Inc. (BMRN) with a Neutral rating and a price target of $116.00.
DA Davidson initiated coverage on Manhattan Associates, Inc. (MANH) with a Neutral rating and a price target of $145.00.
Needham & Company initiated coverage on Riot Platforms (RIOT) with a Buy rating and a price target of $9.00. Shares fell more than 5% today.
Stifel initiated coverage on TXO Energy Partners (TXO) with a Buy rating and a price target of $31.00.
Piper Sandler initiated coverage on Galera Therapeutics (GRTX) with an Overweight rating and a price target of $6.00. Shares gained 9% today.
Noble Capital initiated coverage on MAIA Biotechnology (MAIA) with an Outperform rating and a price target of $14.00.
By Davit Kirakosyan
Want this type of news in real-time as it happens? Upgrade to StreetInsider.com Premium Here
